Tuesday, May 26, 2015

Amgen Parts Ways With AstraZeneca On Compound

Thousand Oaks-based Amgen said late Friday that it is terminating a program it has with AstraZeneca, to co-develop and commercialize a treatment for psoriasis. According to Amgen, the move is based on events of suicidal ideation and behavior in its clinical trails, which it says would necessitate restrictive labeling and limit the patient population for the drug.